📜 iter-4360dd15-0023.log
22609 bytes
# Iter-0023 mission=4360dd15
# goal: 找到让人类长生不老的方法
# time: 2026-04-25T23:32:37
# focus_node: n129 :: 审计自噬增强是否具有与 mTOR 相当的直接寿命终点证据
========== TRANSCRIPT ==========
→ call task_view({"max_depth":4})
→ call search_memory({"limit":6,"mission_only":false,"query":"蛋白稳态 自噬 线粒体 长寿 候选 干预 寿命 终点 rapamycin"})
→ call memory_stats({})
【tool:task_view】
{"ok": true, "tree": "GOAL: 找到让人类长生不老的方法\n· [✓ done ] root: 找到让人类长生不老的方法\n├─ [✓ done ] n1: 建立 marker 锚定后的局部交换判定框架 ← 已完成 marker 锚定后的局部交换判定框架：固定 μ 锚点、排除触及 μ 的交换、用 greedy witness span 压缩候选窗口，并在触及 wit\n│ ├─ [✓ done ] n5: 规范化 witness：固定 μ 锚点并限制一次交换的位置 ← 完成 witness 规范化：确认固定 μ 锚点时必须排除触碰 μ 的交换，并用 greedy witness span 将允许交换压缩到局部窗口内；小规模穷举\n│ │ ├─ [✓ done ] n9: 证伪一次交换跨越 μ 的规范化可能性 ← 用穷举验证并归纳出结构性事实：任何触及唯一 marker μ 的相邻交换都会使 μ 的位置改变 1，因此在固定 μ 位置的 witness 规范化里，不存在“跨\n│ │ ├─ [✓ done ] n10: 把单侧交换位置压缩为可判定窗口 ← 证明并穷举验证：对左块 greedy witness 的最左/最右嵌入位置 p1..pk，窗口外相邻交换不会改变最大前缀消耗 k，因此允许交换位置可压缩为 [p\n│ │ └─ [✓ done ] n11: 沉淀 witness 规范形模板 ← 沉淀出 witness 规范形模板：固定 μ 锚点、排除触及 μ 的交换、以 greedy witness span 限定局部窗口，并用左块最大前缀消耗 k 作\n│ ├─ [✓ done ] n6: 建立单侧切分判定接口：把可行性压成存在切分点 k ← 把固定 μ 锚点后的可行性压成了单侧切分接口：左块只通过最大前缀消耗长度 k 传递，且 k 由 X 决定、与 Y 无关。\n│ ├─ [✓ done ] n7: 刻画交换不依赖右侧的充分条件 ← 验证了一个可复用充分条件：若一次相邻交换不改变对任意 S 的左块最大前缀消耗 k，则对所有右侧 Y 的可行性判定保持不变；并用穷举检查了 small-case \n│ ├─ [✓ done ] n8: 沉淀可复用的验证模板与失败边界 ← 找到验证模板的失败边界：任意 witness span 不够，必须用 greedy witness span；给出反例 X=abb, S=ba，窗口外交换仍可改\n│ ├─ [✓ done ] n12: 探索两次相邻交换下 greedy witness span 的局部性边界 ← 在二元字母表、长度 n<=8 的穷举中，未找到“两个相邻交换都发生在原始 greedy witness span 之外却改变 k”的反例；这给出了多交换局部性边\n│ ├─ [✓ done ] n13: 把 marker 锚定后的局部交换判定落实为可执行的 O(n)~O(n log n) 检查流程 ← 完成了一个可执行的局部交换检查流程：先算 k，再用 greedy witness span 的局部闭包限制候选交换；对二元字母表、|X|<=8、|S|<=8 的\n│ ├─ [✓ done ] n14: 证伪 greedy witne
【tool:search_memory】
{"ok": true, "results": [{"title": "NEXT_FOCUS", "tags": "pinned focus", "mission": "4360dd15", "modified": "20260425152851000", "preview": "!! 下轮焦点（来自 mission `4360dd15` · Iter-0022） [n127] 筛选蛋白稳态/自噬/线粒体中的第三个高杠杆长寿瓶颈候选（路径：找到让人类长生不老的方法 > 筛选蛋白稳态/自噬/线粒体中的第三个高杠杆长寿瓶颈候选）"}, {"title": "mTOR/rapamycin 优先于泛化自噬/线粒体作为长寿候选", "tags": "fact lesson principle aging triage", "mission": "", "modified": "20260425152830000", "preview": "!! 以寿命终点筛第三个长寿瓶颈时，mTOR/rapamycin 优先于泛化的自噬/线粒体口号 ''结论'': 当候选还停留在“看起来很基础、很上游”的层面时，不要把自噬或线粒体这类宽泛概念自动升格为长寿瓶颈；优先级应给到已经有''成年哺乳动物寿命终点''支持的具体节点。一个典型例子是 rapamycin / mTOR 抑制：PMID 19587680（Nature 2009）直接报告了晚期给药仍可延长遗传异质小鼠寿命。 ''判定规则'': # 先问是否有''直接寿命/健康寿命终点''。 # 再问是否是''具体可干预节点''，而不是宽泛过程名。 # 若宽泛过程没有终点证据，而具体节点有，则优先具体节点。"}, {"title": "第二个长寿瓶颈候选的筛选原则", "tags": "lesson principle method 4360dd15", "mission": "", "modified": "20260425021002000", "preview": "!! 第二个长寿瓶颈候选的筛选原则 在已经锁定[[表观遗传信息损失]]作为首要可检验瓶颈后，第二个候选不应只看“重要性”，还要看''可干预性''与''可反证性''： # 优先级 #* ''细胞衰老''：通常最适合作为第二候选，因为已有相对清晰的干预入口（senolytics、免疫清除、靶向衰老细胞信号）和可观测的组织层读出，便于做 go/no-go。 #* ''蛋白稳态/自噬''、''线粒体功能''：往往更像上游网络层或广谱调制器，生物学重要但因果链更分散，容易把“系统改善”与“直接寿命因果”混在一起。 # 操作性标准 候选必须同时满足： 1. 能提出至少一种相对直接的干预方式； 2. 能设计至少一种与“变年轻”区分开的安全/反证读出； 3. 能在组织或系统层面建立因果链，而不只是相关性。 ''结论'': 如果把长寿探索继续做成可检验路线图，[[cellular senescence"}, {"title": "C1q brain aging mechanism is informative but still insufficient for universal longevity candidacy", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425131714000", "preview": "!! C1q brai
【tool:memory_stats】
{"ok": true, "active": 502, "archived": 402, "active_bytes": 568924, "top_tags": [["lesson", 368], ["fact", 228], ["principle", 184], ["method", 152], ["4360dd15", 146], ["aging", 89], ["evidence-chain", 82], ["wealth", 69], ["clinical-trials", 67], ["immunology", 63], ["knowledge", 59], ["evidence-retrieval", 45], ["predicate verification", 45], ["erratum verification", 42], ["local insertion", 40]], "missions": [["(none)", 294], ["4360dd15", 182], ["4d935e58", 25], ["legacy", 1]]}
→ call pubmed_search({"limit":8,"query":"rapamycin mTOR lifespan healthspan mouse randomized trial PubMed"})
→ call pubmed_search({"limit":8,"query":"autophagy longevity intervention lifespan mouse PubMed"})
→ call pubmed_search({"limit":8,"query":"mitochondria longevity intervention lifespan mouse PubMed"})
【tool:pubmed_search】
{"ok": true, "query": "rapamycin mTOR lifespan healthspan mouse randomized trial PubMed", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "autophagy longevity intervention lifespan mouse PubMed", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "mitochondria longevity intervention lifespan mouse PubMed", "results": []}
→ call search_memory({"limit":8,"mission_only":false,"query":"rapamycin mTOR 19587680 lifespan healthspan"})
→ call search_memory({"limit":8,"mission_only":false,"query":"autophagy intervention lifespan healthspan mouse"})
→ call search_memory({"limit":8,"mission_only":false,"query":"mitochondria intervention lifespan healthspan mouse"})
【tool:search_memory】
{"ok": true, "results": [{"title": "mTOR/rapamycin 优先于泛化自噬/线粒体作为长寿候选", "tags": "fact lesson principle aging triage", "mission": "", "modified": "20260425152830000", "preview": "!! 以寿命终点筛第三个长寿瓶颈时，mTOR/rapamycin 优先于泛化的自噬/线粒体口号 ''结论'': 当候选还停留在“看起来很基础、很上游”的层面时，不要把自噬或线粒体这类宽泛概念自动升格为长寿瓶颈；优先级应给到已经有''成年哺乳动物寿命终点''支持的具体节点。一个典型例子是 rapamycin / mTOR 抑制：PMID 19587680（Nature 2009）直接报告了晚期给药仍可延长遗传异质小鼠寿命。 ''判定规则'': # 先问是否有''直接寿命/健康寿命终点''。 # 再问是否是''具体可干预节点''，而不是宽泛过程名。 # 若宽泛过程没有终点证据，而具体节点有，则优先具体节点。"}, {"title": "PEARL trial is not direct longevity evidence", "tags": "4360dd15 lesson fact classification", "mission": "", "modified": "20260424203525000", "preview": "!! 反例：PEARL 试验不是直接长寿证据 本轮刻意挑选最容易被误判为“长寿试验”的原始人类试验进行证伪：[[NCT04488601]]（PEARL / rapamycin）。 !! 公开证据 - PMC 全文：https://pmc.ncbi.nlm.nih.gov/articles/PMC12074816/ - 文章 PMID：40188830 - 公开摘要明确写出： - “This 48-week decentralized, double-blinded, randomized, placebo-controlled trial ... evaluated the long-term safety of intermittent low-dose rapamycin in a healthy, normative-aging human cohort.” - “The"}, {"title": "IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425132624000", "preview": "!! IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck ''结论'': Among the screened immune/inflammation nodes, IL-11 currently ranks highest because it crosses th
【tool:search_memory】
{"ok": true, "results": [{"title": "NLRP3 is context-dependent longevity-positive, not yet a universal bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425051109000", "preview": "!! NLRP3 is a context-dependent longevity-positive node, but not yet a universal immune/炎症长寿瓶颈 ''结论'': NLRP3 inflammasome suppression can be longevity-positive in mice, but the present evidence still falls short of elevating it to a universal immune/炎症长寿瓶颈. ''关键证据'': # PMID 31625260 / Aging Cell 2020: NLRP3 ablation in mice reported protection from age-related cardiac decline, improved metabolic/"}, {"title": "IgG/FcRn is a strong immune age-amplifying axis, but not yet a universal longevity bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425134301000", "preview": "!! IgG/FcRn is a strong immune age-amplifying axis, but not yet a universal longevity bottleneck ''结论'': IgG/FcRn now meets a stronger bar than purely inflammatory readouts because public evidence includes a mouse //healthspan// and //lifespan// signal: Cell Metab 2024 ([[PMID 38378001]]) reports that IgG accumulates during aging, especially in white adipose tissue, and that preventing IgG buildup"}, {"title": "IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425132624000", "preview": "!! IL-11 remains the
【tool:search_memory】
{"ok": true, "results": [{"title": "IgG/FcRn is a strong immune age-amplifying axis, but not yet a universal longevity bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425134301000", "preview": "!! IgG/FcRn is a strong immune age-amplifying axis, but not yet a universal longevity bottleneck ''结论'': IgG/FcRn now meets a stronger bar than purely inflammatory readouts because public evidence includes a mouse //healthspan// and //lifespan// signal: Cell Metab 2024 ([[PMID 38378001]]) reports that IgG accumulates during aging, especially in white adipose tissue, and that preventing IgG buildup"}, {"title": "IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck", "tags": "fact lesson principle aging immunology", "mission": "", "modified": "20260425132624000", "preview": "!! IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck ''结论'': Among the screened immune/inflammation nodes, IL-11 currently ranks highest because it crosses the strongest available threshold: direct mouse healthspan + lifespan benefit, not merely local inflammation readouts. ''Key evidence'': # [[PMID 39020175]] / Nature 2024: anti-IL-11 fro"}, {"title": "IL-11 is a strong candidate but not yet a universal bottleneck", "tags": "fact lesson aging immunology", "mission": "", "modified": "20260425133514000", "preview": "!! IL-11 is a strong candidate but not yet a
→ call web_search({"limit":5,"query":"PMID 19587680 rapamycin lifespan Nature 2009 mouse"})
→ call pubmed_search({"limit":10,"query":"19587680 rapamycin lifespan mouse Nature 2009"})
→ call pubmed_search({"limit":10,"query":"autophagy activation lifespan mouse rapamycin mTOR longevity review primary"})
→ call pubmed_search({"limit":10,"query":"mitochondrial intervention lifespan mouse longevity primary study"})
【tool:web_search】
{"ok": false, "error": "[Errno 101] Network is unreachable"}
【tool:pubmed_search】
{"ok": true, "query": "19587680 rapamycin lifespan mouse Nature 2009", "results": [{"pmid": "19678809", "title": "Increasing longevity through caloric restriction or rapamycin feeding in mammals: common mechanisms for common outcomes?", "source": "Aging Cell", "pubdate": "2009 Sep", "authors": ["Cox LS", "Mattison JA"], "url": "https://pubmed.ncbi.nlm.nih.gov/19678809/"}, {"pmid": "19606132", "title": "Ageing: A midlife longevity drug?", "source": "Nature", "pubdate": "2009 Jul 16", "authors": ["Kaeberlein M", "Kennedy BK"], "url": "https://pubmed.ncbi.nlm.nih.gov/19606132/"}, {"pmid": "19587680", "title": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.", "source": "Nature", "pubdate": "2009 Jul 16", "authors": ["Harrison DE", "Strong R", "Sharp ZD", "Nelson JF", "Astle CM", "Flurkey K", "Nadon NL", "Wilkinson JE"], "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/"}]}
【tool:pubmed_search】
{"ok": true, "query": "autophagy activation lifespan mouse rapamycin mTOR longevity review primary", "results": [{"pmid": "22052357", "title": "mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging.", "source": "Cell Cycle", "pubdate": "2011 Nov 1", "authors": ["Menendez JA", "Vellon L", "Oliveras-Ferraros C", "Cufí S", "Vazquez-Martin A"], "url": "https://pubmed.ncbi.nlm.nih.gov/22052357/"}]}
【tool:pubmed_search】
{"ok": true, "query": "mitochondrial intervention lifespan mouse longevity primary study", "results": [{"pmid": "40676711", "title": "Sex-specific changes in energy demand during the preplaque stage in a transgenic Alzheimer's mouse model.", "source": "Biol Sex Differ", "pubdate": "2025 Jul 17", "authors": ["Sun R", "Zimbalski LK", "Schreyer S", "Baidoe-Ansah D", "Harutyunyan A", "Heuser A", "Lippert RN", "Spranger J"], "url": "https://pubmed.ncbi.nlm.nih.gov/40676711/"}, {"pmid": "39872286", "title": "Ginsenoside-Re-rich ethanol extract of Panax ginseng berry enhances healthspan extension via mitostasis and NAD metabolism.", "source": "J Ginseng Res", "pubdate": "2025 Jan", "authors": ["Kim M", "Kim SH", "Kim J", "Jin EJ", "Wei S", "Jo Y", "Oh CM", "Ha KT"], "url": "https://pubmed.ncbi.nlm.nih.gov/39872286/"}, {"pmid": "38851726", "title": "Development of primary osteoarthritis during aging in genetically diverse UM-HET3 mice.", "source": "Arthritis Res Ther", "pubdate": "2024 Jun 8", "authors": ["Poudel SB", "Ruff RR", "Yildirim G", "Miller RA", "Harrison DE", "Strong R", "Kirsch T", "Yakar S"], "url": "https://pubmed.ncbi.nlm.nih.gov/38851726/"}, {"pmid": "38343826", "title": "Development of primary osteoarthritis during aging in genetically diverse UM-HET3 mice.", "source": "Res Sq", "pubdate": "2024 Jan 22", "authors": ["Poudel SB", "Ruff RR", "Yildirim G", "Miller RA", "Harrison DE", "Strong R", "Kirsch T", "Yakar S"], "url": "https://pubmed.ncbi.nlm.nih.gov/38343826/"}
→ call task_decompose({"parent_id":"n127","subtasks":[{"rationale":"先验证是否存在已经跨过寿命终点门槛的具体节点，避免把泛化自噬/线粒体概念误判为候选。","title":"审计 mTOR/rapamycin 是否已具备直接寿命终点证据并可作为基线候选"},{"rationale":"如果自噬是独立候选，必须能拿出干预 + 寿命/健康寿命终点，而不是仅有机制与通路相关性。","title":"审计自噬增强是否具有与 mTOR 相当的直接寿命终点证据"},{"rationale":"如果线粒体是独立候选，也必须证明有可操纵节点能触达 organism-level 终点，而不是只停留在代谢或细胞功能改善。","title":"审计线粒体干预是否具有与 mTOR 相当的直接寿命终点证据"}]})
【tool:task_decompose】
{"ok": true, "parent": "n127", "added": [{"id": "n128", "title": "审计 mTOR/rapamycin 是否已具备直接寿命终点证据并可作为基线候选"}, {"id": "n129", "title": "审计自噬增强是否具有与 mTOR 相当的直接寿命终点证据"}, {"id": "n130", "title": "审计线粒体干预是否具有与 mTOR 相当的直接寿命终点证据"}], "count": 3}
→ call task_focus({"id":"n128"})
→ call web_fetch({"max_chars":5000,"url":"https://pubmed.ncbi.nlm.nih.gov/19587680/"})
→ call pubmed_search({"limit":5,"query":"PMID 19587680 rapamycin fed late in life extends lifespan genetically heterogeneous mice"})
【tool:task_focus】
{"ok": true, "focused": "n128", "title": "审计 mTOR/rapamycin 是否已具备直接寿命终点证据并可作为基线候选", "status": "in_progress", "path": ["找到让人类长生不老的方法", "筛选蛋白稳态/自噬/线粒体中的第三个高杠杆长寿瓶颈候选", "审计 mTOR/rapamycin 是否已具备直接寿命终点证据并可作为基线候选"]}
【tool:web_fetch】
{"ok": true, "url": "https://pubmed.ncbi.nlm.nih.gov/19587680/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice - PubMed Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard Publications Account settings Log out Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to Clipboard My Bibliography Collections Citation manager Display options Display options Format Abstract PubMed PMID Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel Email citation Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an
【tool:pubmed_search】
{"ok": true, "query": "PMID 19587680 rapamycin fed late in life extends lifespan genetically heterogeneous mice", "results": []}
→ call write_note({"tags":["fact","lesson","principle","aging","triage"],"text":"!! 具体可干预节点优先于过程名：rapamycin / mTOR 是自噬/线粒体筛选中的基线正例\n''结论'': 在把“蛋白稳态 / 自噬 / 线粒体”作为长寿候选时，不能把过程名自动升格为瓶颈；必须先找具体可干预节点是否已经跨过 ''成年哺乳动物寿命终点'' 门槛。\n''锚点证据'': PMID 19587680 / Nature 2009 报告 ''Rapamycin fed late in life extends lifespan in genetically heterogeneous mice''。\n''可复用判定'':\n# 如果候选只是“自噬增强”或“线粒体改善”，但没有 organism-level lifespan / healthspa)
【tool:write_note】
{"ok": true, "path": "/root/Sisyphus/wiki/tiddlers/Rapamycin_is_a_baseline-positive_specific_node_autophagy_and_mitochondria_are_not_automatically_longevity_candidates.tid", "title": "Rapamycin is a baseline-positive specific node; autophagy and mitochondria are not automatically longevity candidates"}
→ call task_done({"id":"n128","result":"已确认 rapamycin/mTOR 具备直接成年哺乳动物寿命终点：PMID 19587680 报告晚期喂食 rapamycin 延长遗传异质小鼠寿命，因此它可作为自噬/线粒体筛选的基线正例，而不是把过程名自动升格。"})
【tool:task_done】
{"ok": true, "id": "n128", "status": "done", "next_focus": "n129"}
【assistant】
已完成本轮焦点 n128。
结果：
- 确认了 rapamycin / mTOR 作为“具体可干预节点”的基线正例；
- 直接证据：PMID 19587680 / Nature 2009，晚期喂食 rapamycin 可延长遗传异质小鼠寿命；
- 因而“自噬 / 线粒体”这类过程名不能自动升格为长寿瓶颈，必须先拿出同等级的 organism-level 终点证据。
我也已沉淀一条可复用规则到记忆中。
<NEXT_FOCUS>审计自噬增强是否具有与 mTOR 相当的直接寿命终点证据</NEXT_FOCUS>
========== REFLECTION ==========
{
"progress": "确认了 mTOR/rapamycin 具备直接的成年哺乳动物寿命终点证据，而泛化的自噬/线粒体检索仍未给出同等级的可干预终点支持。",
"failure": "用宽泛过程名做文献检索的回报很低，未能从自噬/线粒体中再筛出一个新的、可直接进入长寿候选比较的具体节点。",
"lesson": {
"worthy": false,
"title": "",
"tags": [
"lesson",
"failure"
],
"text": ""
},
"next_focus": "在蛋白稳态/自噬/线粒体中，只寻找一个具体可干预节点并要求成年哺乳动物寿命终点证据；找不到就转为证明该类过程名不足以作为候选。"
}